Article information
Full text is only aviable in PDF
Bibliografía
[1.]
A. Moreno, E. Vargas, J. Soto, J. Rejas.
Análisis coste-efectividad del empleo de celecoxib en el tratamiento de la artrosis.
Gac Sanit, 17 (2003), pp. 27-36
[2.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study.
J Am Med J, 284 (2000), pp. 1247-1255
[3.]
Witter J. Medical officer review. Consultado el 31 de marzo, 2003. Disponible en: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf
[4.]
Lu HL. Statistical reviewer briefing document for the advisory committee. Consultado el 31 de marzo de 2003. Disponible en: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc
[5.]
P. Jüni, A.W.S. Rutjes, P.A. Dieppe.
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case.
BMJ, 324 (2002), pp. 1287-1288
[6.]
P. Jüni, A.W.S. Rutjes, P.A. Dieppe.
CLASS clarification: reaffirms the medical importance of the analyses and results. The authors respond.
BMJ, 325 (2002), pp. 523-524
[7.]
F. Silverstein, L. Simon, G. Faich.
Reporting of 6-month vs 12-month data in a clinical trial of celecoxib (in reply).
J Am Med Assoc, 286 (2001),
[8.]
G.S. Geis.
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
BMJ, 325 (2002), pp. 161
[9.]
G.S. Geis.
CLASS clarification: reaffirms the medical importance of the analyses and results.
BMJ, 325 (2002), pp. 522-523
[10.]
J.J. Deeks, L.A. Smith, M.D. Bradley.
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
BMJ, 325 (2002), pp. 619
[11.]
P. Juni, R. Sterchi, P. Dieppe.
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.
BMJ, 326 (2003), pp. 334
[12.]
D. Mukherjee, S.E. Nissen, E.J. Topol.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
J Am Med Assoc, 286 (2001), pp. 954-959
[13.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med, 343 (2000), pp. 1520-1528
[14.]
J.P. McCormack, R. Rangno.
Digging for data from the COX-2 trials.
Can Med J Assoc, 166 (2002), pp. 1649-1650
[15.]
S. Peiró, S. Peiró, A. García-Altes, R. Meneu, J. Librero, E. Bernal.
La declaración del conflicto de intereses en las publicaciones científicas. ¿Tiempo para las luces y los taquígrafos en la trastienda de la investigación financiada por la industria?.
Gac Sanit, 14 (2000), pp. 472-481
[16.]
E. Vargas, L. Laredo, J. Soto, J. Rejas.
Evaluación económica de celecoxib en el tratamiento de la artrosis.
Aten Farmacéutica, 4 (2002), pp. 72-82
[17.]
J. Soto, A. Belén Romero, J. Rejas.
Análisis fármacoeconómico del uso de celecoxib en el tratamiento de la artrosis.
Rev Esp Reumatol, 29 (2002), pp. 142-150
Copyright © 2003. Sociedad Española de Salud Pública y Administración Sanitaria
